Contact
Please use this form to send email to PR contact of this press release:
Immunovaccine Announces U.S. FDA, Health Canada Clearance to Initiate Phase 1b Clinical Trial for DPX-Survivac in Combination with Incyte's IDO1 Inhibitor Epacadostat in Recurrent Ovarian Cancer
TO: